Elvina Almuradova· @Dr_ElvinaA · X·· 2 天前评分70
正文 · 机器翻译
B-STRONGER-I 中令人印象深刻的 ctDNA 动态！
I–III 期 TNBC 的基线检出率为 95.1%。
至 C3D1：80.8% 清除，ctDNA 水平中位数下降 99.8%。
在手术前即可窥见早期治疗反应的显著窗口。
#ESMO26 #TNBC #ctDNA @Larvol @OncoAlert
309 浏览 · 4 赞 · 6 转发 · 0 回复
会议摘要
LBA26按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
https://esmocongress.esmo.orgLBA96按 Proffered paper 2: Breast cancer, early and advanced stage 对上
First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com